Mon, Sep 22, 2014, 8:42 AM EDT - U.S. Markets open in 48 mins.


% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

dbaaaa 8 posts  |  Last Activity: Sep 9, 2014 12:08 PM Member since: Jan 17, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Standby for news..

  • My Yo-Yo stock..

  • acts that way..

  • The director’s scathing resignation letter reads as follows:

    Re: Resignation from the Board of Directors

    Dear Harvey:

    We are writing to confirm our immediate resignations as four independent members of the board of directors (the “Board”) of ARIAD Pharmaceuticals, Inc. (“ARIAD”) due to our vigorous disagreements with you over fundamental matters of corporate policy, professional ethics and proper standards of corporate governance on behalf of all ARIAD stockholders.

    Throughout our Board tenure, we have understood that our primary role as independent directors has been to promote the success of ARIAD and to act in the best interests of all ARIAD stockholders. We worked diligently to ensure there would be a level playing field for all ARIAD stockholders as a result of the recent AGTI transaction, in which you and Jay LaMarche had a clear conflict of interest. Unfortunately, the recent completion of the AGTI merger transaction has obviously been the trigger for your grossly inappropriate behavior in your dealings with the four independent directors who approved the AGTI merger despite your unjustified objections.

    Our resignation is prompted by your self-interested, combative and obstructionist actions — particularly over the last month — involving implementation of the AGTI merger, the replacement of the Company’s general counsel, the mishandling of the AGTI appraisal litigation, your manipulative conduct prior to and at the November 3 meeting of the Board, the recomposition of the Board to allow your surrogates to control the Board’s decisions without regard to or even inviting our input, the removal of the vice chairman of the Board at a precipitously called meeting in which you knew we could not participate, your installation of a close personal family friend as lead director of the Board, and your determination to cause ARIAD to breach agreements approved by the Board over your opposition.

  • Reply to The truth about SGYP shorts exposed by Seeking Alpha by robcc1582 •20 hours ago
    ronsmithson54 • 59 minutes ago Flag
    0users liked this postsusers disliked this posts0Reply
    Some very good points in the article, but some things to consider:

    1. Institutional ownership ONLY about 1/3 of the float, not compelling. Amarin, considered by many to be the laughing stock of the biotech community, commands a similar share of faith, whereas names like Acadia, Bluebid Bio and Puma command 2/3 ownership up to 90% and higher, indicating strong faith by the Smart Money that their candidates work, are safe, and will sell like hotcakes. Retail has been, is, and always will be, considered the Dumb Money, and I like to bet with the house when it comes to biotech investing.

    2. In '13/14, the stock ran up 50% into the P2 IBS-C results, but to provide some context, biotechs (e.g. XBI, IBB) did extremely well as a group during that period so you have to place what was happening in context of the sentiment of that time. Of course, there were junk names that did not move in sync with the general sector, but a simple side by side comparison of SGYP:XBI on a charting website clearly indicates a negative correlation. In other words, it actually failed to keep pace with just owning a basket of bio names.

    3. You plainly stated that SP-333 is essentially a 'free option' in that valuation models do not incorporate it in a meaningful way to estimate future cash flows. So why then the teaser that a similar 30-50% run up is on the way when there is much less at stake here versus the P2 IBS-C results? The run up phenomenon is not only NOT guaranteed (witness PBYI's lackluster trading before its blockbuster move), but as more and more people become aware of it, the less likely it is to occur. Recent examples that come to mind include POZN and ETRM, neither of which generated a meaningful runup despite daily pumping of said phenomenon by the 'bio-gurus' on Twitter.

    I have no position, and may in fact get long if the options market begins to display a bullish tone (as PBYI did in the weeks before data was released, even though price action was neutral at best). Less

  • Re: brownsfan407 Post# 703
    IP situation: posting my earlier reply from Cafepharma to another overly optimistic plecanatide IP spin post - enjoy.

    Originally Posted by Anonymous

    IP agreement with IRWD blocks competition. Despite the company’s patent–license agreement with Ironwood, there’s still some investor belief that an intellectual property overhang exists on the stock, thus, the company’s plecanatide patents are worth touching on. The patent deal with IRWD, announced in September of 2012, actually blocks other companies from entering into the GC-C agonist segment and competing in the key IBS-C or CIC indications, or any other inflammatory GI diseases or cancers with the technology. As a result, for large companies hoping to enter this drug class, SGYP is the only asset available for acquisition or partnering and this is why the company is likely to be on analyst take-out lists this year. Synergy has two patents covering the composition of plecanatide – one is a broad patent covering several analogues of uroquanylin (the parent structure of plecanatide), and the other is a patent covering the specific structure of plecanatide itself. These patents, with Hatch Waxman exclusivity, are expected to expire in 2025, and the company continues to evolve its patent estate.

    Plecanatide is an analogue of uroquanylin, with one amino acid different from the active form of uroquanylin. The replacement of aspartic acid with glutamic acid fixes the structure in a rigid (partially closed) state, which was designed to act in the intestine and is more stable and more potent than uroquanylin. This novel peptide structure was also designed for optimum low-cost manufacturing.
    Ironwood obtained a patent on the use of plecanatide in IBS-C and CIC after multiple rejections by the U.S. Patent and Trade Office (PTO), but of course, Ironwood cannot sell the product in these indications because plecanatide (its composition of matter) is owned by Synergy. Synergy never applied

11.52-0.08(-0.69%)Sep 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.